| Name | Title | Contact Details |
|---|
Vidant Health is a system of care. It includes Vidant Medical Center, the region`s only Level 1 trauma center, community hospitals, physician practices and partners who collaborate with us to enhance the quality of life for the people and communities we serve, touch and support. Vidant Health is affiliated with the Brody School of Medicine at East Carolina University and provides a continuum of care that addresses wellness, prevention and community health issues as well as acute care, post-acute care, home health and hospice.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.
rl Solutions is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Golden Years Medical Inc is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.